Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Spiritual Wellbeing in Advanced Cancer Patients Receiving Genomic Test Results.

Psycho-oncology·2026
Same author

Correction: Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Genomic Therapy Matching in Rare and Refractory Cancers.

JAMA oncology·2026
Same author

Two-stage inertial microfluidics enrichment of activated T-cells towards a bead-less chimeric antigen receptor manufacturing protocol.

Medical oncology (Northwood, London, England)·2026
Same author

Large-scale drug sensitivity, gene dependency, and proteogenomic analyses of telomere maintenance mechanisms in cancer cells.

Nature communications·2025
Same author

Potent synthetic lethality between PLK1 and EYA family inhibitors in tumors of the central and peripheral nervous systems.

Genes & development·2025
Same journal

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Future oncology (London, England)·2026
Same journal

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

Future oncology (London, England)·2026
Same journal

Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting.

Future oncology (London, England)·2026
Same journal

Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis.

Future oncology (London, England)·2026
Same journal

Disparities in mortality among HER2-positive breast cancer patients treated with trastuzumab in Chile (2015-2024): real-world evidence from 4,920 cases.

Future oncology (London, England)·2026
Same journal

VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcoma.

Future oncology (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

Targeting telomerase in hematologic malignancy.

Michelle F Maritz1, Christine E Napier, Victoria W Wen

  • 1Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, New South Wales, Australia.

Future Oncology (London, England)
|May 15, 2010
PubMed
Summary
This summary is machine-generated.

Telomerase is vital for blood cell formation (hematopoiesis) and linked to bone marrow failure. Targeting telomerase shows promise for treating aggressive leukemias and other blood cancers.

More Related Videos

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells
09:13

Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells

Published on: January 17, 2019

Related Experiment Videos

Last Updated: Jun 13, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells
09:13

Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells

Published on: January 17, 2019

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Telomere maintenance by telomerase is crucial for normal hematopoiesis.
  • Mutations in telomere maintenance genes cause bone marrow failure syndromes.
  • Telomere-independent functions of telomerase also impact hematopoiesis and blood diseases.

Purpose of the Study:

  • To review the role of telomerase in hematopoiesis and hematologic malignancies.
  • To discuss therapeutic strategies targeting telomerase in blood cancers.
  • To highlight the importance of further research into telomerase functions and inhibition.

Main Methods:

  • Review of preclinical and clinical investigations.
  • Analysis of genetic strategies, oligonucleotides, small-molecule inhibitors, and immunotherapy.
  • Examination of telomere-dependent and telomere-independent telomerase functions.

Main Results:

  • Telomerase plays a critical role in normal and malignant hematopoiesis.
  • Targeting telomerase has shown success in preclinical studies for hematologic malignancies.
  • Therapeutic strategies targeting telomerase have advanced to clinical trials.

Conclusions:

  • Telomerase is a significant therapeutic target in hematologic malignancies.
  • Further research into telomerase's multifaceted roles is essential for optimizing treatments.
  • Investigating telomerase inhibition in both normal and malignant hematopoiesis will refine therapeutic safety and efficacy.